转移性乳腺癌颅外立体定向放疗的结局:治疗指征至关重要
该单中心回顾性研究分析了2011至2017年接受颅外SBRT的120例转移性乳腺癌患者(193个病灶),中位随访15.25个月。1年和2年局部控制率分别为89%和86.6%,1年和2年总生存率分别为83.5%和70%。寡转移患者的OS和PFS均优于寡进展和优势肿瘤局部控制患者,SBRT可能延迟全身治疗启动或更换。
要点
- 1年和2年局部控制率分别为89%和86.6%,SBRT局部控制效果优良
- 寡转移、寡进展和CDT的1年OS分别为91.0%、78.5%和63.9%(p=0.003)
- 寡转移1年PFS为66%,显著优于寡进展19.6%和CDT14.3%(p<0.001)
核心结论
- 寡转移患者接受SBRT后的OS和PFS优于寡进展或优势肿瘤局部控制患者。
- SBRT可能延迟转移性乳腺癌患者启动或更换化疗/内分泌治疗,尤其寡转移患者。
- SBRT在转移性乳腺癌患者中提供了优良的局部控制。
研究设计与样本
- 单中心回顾性研究,纳入2011至2017年接受颅外SBRT的转移性乳腺癌患者120例,共193个治疗病灶,中位随访15.25个月。
- 治疗指征分为寡转移、寡进展和优势肿瘤局部控制(CDT)三类。
- 采用单因素和多因素分析识别预测因素,终点包括OS、PFS、局部控制(LC)和启动/更换化疗或内分泌治疗的累积发生率(SCT)。
主要发现
- 1年和2年局部控制率分别为89%和86.6%。
- 1年和2年OS率分别为83.5%和70%,治疗指征和分子亚型是多因素分析中的预测因素。
- 寡转移、寡进展和CDT的1年OS分别为91.0%、78.5%和63.9%(p=0.003)。
- 基底样亚型OS最差,1年和2年OS分别为59.2%和39.5%(p=0.01)。
- 1年和2年PFS率分别为45%和32%;寡转移、寡进展和CDT的1年PFS分别为66%、19.6%和14.3%(p<0.001)。
关键数值与推荐
- 治疗指征在多因素分析中是PFS和较低SCT率的预测因素。
- 治疗指征和分子亚型在多因素分析中是OS的预测因素。
临床怎么用
- 对转移性乳腺癌患者行颅外SBRT时,应明确治疗指征(寡转移、寡进展或CDT),因其与OS和PFS密切相关。
- 寡转移患者可能从SBRT中获得更好的生存和延迟全身治疗启动或更换的获益。
- 分子亚型(尤其基底样)应纳入预后评估和患者选择。
局限性
- 单中心回顾性研究,样本量120例,可能存在选择偏倚。
- 中位随访15.25个月,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To summarize the clinical outcomes of stereotactic body radiotherapy (SBRT) for metastatic breast cancer (mBC) from a large institution. MATERIALS AND METHODS: Patients with mBC who received extra-cranial SBRT to metastatic lesions from 2011 to 2017 were identified. Treatment indications were: oligometastases, oligoprogression, and local control of dominant tumor (CDT). Endpoints included overall survival (OS), progression-free survival (PFS), local control (LC) and cumulative incidence of starting/changing chemo or hormonal therapy (SCT). Univariate and multivariate analyses were used to identify predictive factors. RESULTS: We analyzed 120 patients (193 treated metastatic lesions) with a median follow up of 15.25 months. 1-and 2-year LC rates were 89% and 86.6%, respectively. 1-and 2-year OS rates were 83.5% and 70%, respectively, with treatment indication and molecular subtype being the predictive factors on MVA. 1-year OS was 91.0%, 78.5% and 63.9% for oligometastases, oligoprogression and CDT, respectively (p = 0.003). The worst OS was seen in basal subtype with 1-and 2-year OS rates of 59.2% and 39.5% (p = 0.01). Treatment indication was found to be predictive for PFS and lower rates of SCT on MVA. 1-and 2-year PFS rates were 45% and 32%, respectively. The 1-year PFS for oligometastases, oligoprogression, and CDT was 66%, 19.6%, and 14.3%, respectively (p < 0.001). The cumulative incidence of SCT at 1-year was 12% for oligometastases, 39.7% for oligoprogression and 53.3% for CDT (p < 0.001). CONCLUSION: Patients treated for oligometastases have better OS and PFS than those treated for oligoprogression or CDT. SBRT may delay SCT in mBC patients, particularly those with oligometastases. SBRT provided an excellent LC in mBC patients.
引用
- Tan H, Cheung P, Louie AV, et al. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters. Radiother Oncol. 2021. PMID: 34119585. doi:10.1016/j.radonc.2021.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。